Integral BioSystems, LLC

Integral BioSystems is a contract research organization (CRO) specializing in the development of complex drug formulations and specialty delivery systems. Founded in 2009 and based in Bedford, Massachusetts, the company provides high-end R&D and cGLP technical services, including analytical method development, preformulation studies, and process scale-up. Its core expertise lies in designing biocompatible formulations for diverse routes of administration, such as ophthalmic, injectable, dermal, intranasal, and otic, with a particular focus on sustained-release technologies like lipid nanoparticles, microspheres, and nano-/micro-crystals. The company differentiates itself through its translational medicinal approach, helping clients transition research concepts from laboratory feasibility through to clinic-ready products for first-in-man trials.

By serving as an extended R&D arm for start-ups, mid-size companies, and large pharmaceutical organizations, Integral BioSystems addresses critical formulation challenges that can impede drug development pipelines. Beyond its fee-for-service CRO model, the company maintains a proprietary portfolio of patented delivery platforms, including OcuHeal and NanoM Wafer, which are available for licensing to enhance the bioavailability or delivery performance of client molecules. The team provides comprehensive CMC planning and cGLP support, ensuring rigorous adherence to scientific standards while maintaining the nimbleness required for early-stage development. With extensive experience supporting various clinical applications, the company acts as a strategic partner in navigating complex regulatory and technical requirements for drug product design.